Equities

Helix BioMedix Inc

HXBM:PKL

Helix BioMedix Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)18.00
  • Today's Change0.00 / 0.00%
  • Shares traded200.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 17 2024 17:46 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Helix BioMedix, Inc. is a peptide discovery and development biopharmaceutical company, which is focused on drug development for treatment of rare dermatological diseases, such as xeroderma pigmentosum. The Company’s lead drug development candidate, HB4208, is a deoxyribonucleic damage response enzyme for topical treatment of the rare genetic disorder (orphan disease) Xeroderma Pigmentosum (XP). Its intellectual property portfolio offers multiple pathways for commercialization in this area ranging from Rx dermatology to aesthetic dermatology and personal care. It is developing new treatment options for dermatologic conditions which offer the therapeutic effectiveness and safety benefits of its advanced bioactive small molecule technology. It is transforming the treatment of skin conditions by addressing unmet needs in elegant, life-enhancing topical formulations. Its research and development consist of a proprietary library of bioactive peptides based on the body’s innate immunity.

  • Revenue in USD (TTM)2.07m
  • Net income in USD-2.58m
  • Incorporated2000
  • Employees8.00
  • Location
    Helix BioMedix Inc19125 Northcreek Parkway Suite 120BOTHELL 98021United StatesUSA
  • Phone+1 (425) 402-8400
  • Fax+1 (425) 806-2999
  • Websitehttps://helixbiomedix.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Avenue Therapeutics Inc0.00-5.87m3.74m3.00--0.6518-----3.02-3.020.004.000.00----0.00-177.94-186.91---287.70------------0.00-------192.15------
ENDRA Life Sciences Inc0.00-9.57m3.83m21.00--0.034-----45.63-45.630.006.210.00----0.00-97.17-132.00-117.34-157.28------------0.00------23.67---19.46--
InMed Pharmaceuticals Inc5.63m-6.08m3.86m13.00--0.156--0.6863-1.23-1.230.92841.750.40062.7129.77---43.26-88.10-50.03-104.1939.20---108.01-1,066.115.80--0.00--279.60--57.27--29.56--
Theriva Biologics Inc0.00-22.27m3.91m21.00--3.28-----1.25-1.250.001.230.00----0.00-41.30-36.95-48.49-40.16------------0.0056------8.37--95.91--
Hepion Pharmaceuticals Inc0.00-28.37m3.93m22.00--2.10-----6.49-6.490.000.61420.00----0.00-133.45-61.43-167.53-68.82------------0.00-------7.92------
Ainos Inc65.12k-15.41m3.97m46.00--0.1759--60.91-3.17-3.170.01262.800.00190.781413.861,415.65-44.29-36.36-49.13-58.33-316.6236.82-23,664.28-813.631.45-55.500.4016---96.539.461.69--66.44--
Trevena Inc443.00k-37.03m4.01m23.00------9.05-56.17-56.170.6391-22.230.0143----19,260.87-119.82-55.93-152.94-66.35-271.56---8,358.24-3,134.41---20.122.51--847.61-11.4324.93---24.67--
Helix BioMedix, Inc.2.07m-2.58m4.04m8.00--2.59--1.96-15.60-15.6012.486.950.80471.874.55258,238.80-100.64-146.31-120.73-173.5768.9630.80-125.06-527.121.69-14.570.00--122.0792.8067.73---29.08--
Peak Bio Inc354.02k-4.63m4.05m--------11.43-0.2066-0.20660.0135-0.97690.2192-------286.54-----------1,307.11-----4.85-----39.46--2.01------
Lixte Biotechnology Holdings Inc0.00-4.03m4.14m3.00---------1.83-1.830.000.99860.00----0.00-139.98-104.18-163.33-111.05-----------563.880.00------19.41------
Oragenics Inc7.47k-19.52m4.16m5.00------556.41-6.99-6.990.00230.23770.0013----1,494.00-349.31-97.60-451.26-106.24-----261,261.60-36,169.75----0.00---71.37---44.56--51.64--
Creative Medical Technology Holdings Inc17.00k-5.73m4.16m4.00--0.5466--244.80-4.07-4.070.0125.690.00151.00--4,250.00-51.83-110.00-53.71--60.0065.82-33,716.41-7,961.1420.20--0.00---89.84-40.8647.88------
Synaptogenix Inc0.00-3.45m4.28m5.00--0.2175-----3.89-3.890.0014.990.00----0.00-5.54-40.33-6.89-43.36------------0.00-------142.17---3.21--
Galera Therapeutics Inc0.00-29.11m4.30m7.00---------0.5892-0.58920.00-2.540.00----0.00-90.03-83.69-119.01-97.54-----------14.3411.60------5.05---29.84--
Data as of Sep 17 2024. Currency figures normalised to Helix BioMedix Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.